VASCULAR COGNITIVE IMPAIRMENT: FROM PATHOGENESIS TO TREATMENT
- Authors: Tkacheva O.1, Runikhina N.1, Cherdak M.1
-
Affiliations:
- Russian Gerontology Research and Clinical Center, N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
- Issue: Vol 28, No 6 (2017)
- Pages: 16-19
- Section: Articles
- URL: https://journals.eco-vector.com/0236-3054/article/view/116889
- ID: 116889
Cite item
Open Access
Access granted
Abstract
The term vascular cognitive impairments (VCI) defines dementia and cognitive impairment no dementia, which are pathogenetically associated with cerebral vessel damage. The paper considers the etiology, pathogenesis, criteria for instrumental and clinical diagnosis, as well as VCI. The relationship between VCI and neurodegenerative diseases is discussed separately.
Full Text
About the authors
O. Tkacheva
Russian Gerontology Research and Clinical Center, N.I. Pirogov Russian National Research Medical University, Ministry of Health of RussiaProfessor MD Moscow
N. Runikhina
Russian Gerontology Research and Clinical Center, N.I. Pirogov Russian National Research Medical University, Ministry of Health of RussiaProfessor MD Moscow
M. Cherdak
Russian Gerontology Research and Clinical Center, N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Email: maria.cherdak@yandex.ru
Candidate of Medical Sciences Moscow
References
- Hachinski V. Stroke: a global agenda (Victor and Clara Soriano Award Lecture) // J. Neurol. Sci. - 2009; 285: 1-4.
- Jellinger K. Morphologic diagnosis of «vascular dementia» - a critical update. // J. Neurol. Sci. - 2008; 270: 1-12.
- Sachdev P., Kalaria R., O’Brien J. et al. Diagnostic criteria for vascular cognitive disorders: a VASCOG statement // Alz. Dis. Ass. Dis. - 2014; 28: 206-18.
- Lim J., Kwon H. Risk of «silent stroke» in patients older than 60 years: risk assessment and clinical perspectives // Clin. Interv. Aging. - 2010; 5: 239-51.
- Чердак М.А., Яхно Н.Н. Нейродегенеративные и сосудистые факторы развития постинсультных когнитивных расстройств // Неврол. журн. - 2012; 17 (5): 10-5.
- Фонякин А.В, Гераскина Л.А. Артериальная ригидность, эндотелиальная функция и цереброваскулярные заболевания // Справочник поликлинического врача. - 2014; 4: 22-5.
- van Sloten T., Stehouwer C. Carotid stiffness: a novel cerebrovascular disease risk factor // Pulse (Basel). - 2016; 4: 24-7.
- Gorelick P., Scuteri A., Black S. et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the Аmerican heart association/Аmerican stroke association // Stroke. - 2011; 42 (9): 2672-713.
- Farrall A., Wardlaw J. Blood-brain barrier: Ageing and microvascular disease - systematic review and meta-analysis // Neurobiol. Aging. - 2009; 30: 337-52.
- Hilal S., Sikking E., Shaik M. Cortical cerebral microinfarcts on 3T MRI: A novel marker of cerebrovascular disease // Neurology. - 2016; 87 (15): 1583-90.
- Daulatzai M. Cerebral hypoperfusion and glucose hypometabolism: Key pathophysiological modulators promote neurodegeneration, cognitive impairment, and Alzheimer's disease // J. Neurosci. Res. - 2016; 95 (4): 943-72.
- Мхитарян Э.А., Преображенская И.С. Болезнь Альцгеймера и цереброваскулярные расстройства // Неврол. журн. - 2006; 11 (1): 31-6.
- Чердак М.А., Успенская О.В. Сосудистая деменция // Неврол., нейропсихиат., психосомат. - 2010; 1: 30-6.
- Мхитарян Э.А. Значение сосудистых церебральных нарушений при болезни Альцгеймера. Дис.. канд. мед. наук / М., 2004.
- Matsui T., Nemoto M., Maruyama M. Plasma homocysteine and risk of coexisting silent brain infarction in Alzheimer's disease // Neurodegener. Dis. -2005; 2 (6): 299-304.
- Harrison S., Tang E., Keage H. et al. A systematic review of the definitions of vascular cognitive impairment, no dementia in cohort studies // Dement. Geriatr. Cogn. Disord. - 2016; 42 (1-2): 69-79.
- DeKosky S., Williamson J., Fitzpatrick A. et al. Ginkgo biloba for prevention of dementia. A randomized controlled trial // JAMA. - 2008; 300: 2253-62.
- Baskys A., Hou A. Vascular dementia: pharmacological treatment approaches and perspectives // Clin. Interv. Aging. - 2007; 2 (3): 327-35.
- Kavirajan H., Schneider L. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials // Lancet Neurol. - 2007; 6 (9): 782-92.
- Xi Y., Wang M., Zhang W. et al. Neuronal damage, central cholinergic dysfunction and oxidative damage correlate with cognitive deficits in rats with chronic cerebral hypoperfusion // Neurobiol. Learn. Mem. - 2014; 109: 7-19.
- Rammes G., Rupprecht R., Ferrari U. The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner // Neurosci. Lett. - 2001; 306: 81-4.
- Вознесенская Т.Г. Эмоционально-аффективные и поведенческие нарушения при легких и умеренных когнитивных расстройствах. Опыт применения мемантина // Неврол. журн. - 2009; 14 (3): 49-55.
Supplementary files
